Logo
x

Search

Subscribe Now

 P-III

The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

  • October 30, 2024
Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)

Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)

  • October 28, 2024
Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs

Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs

  • October 28, 2024
EyePoint Pharmaceuticals Reports the First Patient Dosing in P-III (LUGANO) Study of Duravyu to Treat Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Reports the First Patient Dosing in P-III (LUGANO) Study of Duravyu to Treat Wet Age-Related Macular Dege...

  • October 25, 2024
BeiGene Reports the CHMP’s Positive Opinions for Tevimbra as a 1L Treatment of G/GEJ Cancer and Esophageal Squamous Cell Carcinoma

BeiGene Reports the CHMP’s Positive Opinions for Tevimbra as a 1L Treatment of G/GEJ Cancer and Esophageal Squamous Cell Carcinoma

  • October 22, 2024
Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer

Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer

  • October 21, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.